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Summary
Background: In 2017, Tayside, a region in the East of Scotland, rapidly scaled- up 
Hepatitis C Virus (HCV) outreach and treatment among People Who Inject Drugs 
(PWID) using novel community care pathways.
Aims: We aimed to determine treatment outcomes for PWID during the scale-
 up against pre- determined targets; and assess re- infection, mortality, and post- 
treatment follow up.
Methods: HCV treatment was delivered in community pharmacies, drug treatment 
centres, nurse- led outreach clinics, prisons, and needle exchanges, alongside con-
ventional hospital care. We retrospectively analysed clinical outcomes and compared 
pathways using logistic regression models.
Results: Of 800 estimated HCV- infected PWID, 718 (90%) were diagnosed. 713 
treatments commenced among 662 (92%) PWID, delivering 577 (81%) Sustained 
Virologic Responses (SVR). SVR was 91% among those who attended for testing. 
Forty- six individuals were treated more than once. Needle exchanges and commu-
nity pharmacies initiated 49% of all treatments. Regression analyses implied pharma-
cies had superior follow- up, but there was no difference in likelihood of achieving 
SVR in community pathways relative to hospital care. Re- infection occurred 39 times 
over 256.57 person years (PY), yielding a rate of 15.20 per 100 PY (95% CI 10.81- 
20.78). 54 deaths occurred (29 drug related) over 1,553.04 PY, yielding a mortality 
rate of 3.48 per 100 PY (95% CI 2.61- 4.54). Drug- related mortality was 1.87 per 100 
PY (95% CI 1.25- 2.68).
Conclusions: Rapid HCV treatment scale- up to PWID in community settings, whilst 
maintaining high SVR, is achievable. However, other interventions are required to 
minimise re- infection; reduce drug- related deaths; and improve post- SVR follow- up 
testing regionally.
2  |     BYRNE Et al.
1  | INTRODUC TION
Hepatitis C Virus (HCV) is a blood- borne virus (BBV) that is transmit-
ted mainly via percutaneous exposure to infected blood. Therapeutic 
advances led the World Health Organization, in 2016, to release its 
Global Health Sector Strategy, providing an implementation plan for 
HCV elimination.1 It specified targets to diagnose 90% of infected 
individuals and initiate treatment for 80% of those diagnosed, to fa-
cilitate HCV elimination by 2030.
In 2017, concurrent to the WHO strategy response, National 
Health Service (NHS) Tayside— a health board in the East of Scotland 
serving approximately 416,000 people— commenced a trial of 
Treatment as Prevention (TasP) in HCV infection, by rapidly scaling 
up treatment among PWID.2,3 The first step was a regional pro-
gramme of intensified HCV testing and treatment to reduce chronic 
HCV to <10% among PWID over the long term and achieve WHO 
elimination criteria.3 The concept of TasP is using treatment to lower 
HCV prevalence among PWID to prevent new infections and re- 
infections, maintaining elimination or reducing the amount of treat-
ment needed to maintain it.3,4
The programme was underpinned by novel community care 
pathways, and highly effective Direct Acting Antiviral (DAA) treat-
ments.5,6 The pathways were implemented by a multidisciplinary 
team. Clinical initiatives focused on PWID, as injection drug use 
(IDU) was the primary driver of regional HCV transmission, and over 
90% of HCV infections in Scotland occur consequent to IDU.7,8
This study aims to determine if rapid regional scaleup of HCV 
treatment was achieved in the PWID population in line with local 
and WHO targets. We report critical real- world outcomes of the 
scale- up including cure rates (Sustained Virologic Response, SVR) 
by treatment pathway, risks of HCV re- infection, mortality rates, 
and effectiveness of post- treatment follow- up, both for SVR and re- 
infection testing.
2  | METHODS
2.1 | Testing and treatment targets
Prior to scaleup, there were an estimated 2800 PWID resident in 
the Tayside heath board region, of whom 800 (29%) were estimated 
to have chronic (6+ months infected) HCV.3,9 In line with these es-
timates, local targets were set to achieve the prevalence reduction 
required to demonstrate TasP over the long term. Targets were to di-
agnose and engage approximately 680 (85%) HCV infections among 
PWID, initiate approximately 592 (87% of diagnosed) treatments, and 
obtain approximately 533 (≥90% of treated cases) undetected SVRs.
2.2 | Study setup
The study is described on clinicaltrials.gov (NCT03356405) and 
ISCRCTN (ISRCTN72038467) and co- sponsored by NHS Tayside 
and University of Dundee (2016GA08). It received NHS ethical fa-
vourable opinion (17/ES/0136). Data was obtained from HCV clini-
cal databases; virology/microbiology records; and patient records. 
Caldicott Guardian approval for this was granted (IGTCAL7005).10 
Tracking individuals was by Community Health Index (CHI) number, 
an identifier allocated to every registered patient in Scotland. All 
adults who initiated HCV treatment with DAAs from January 2017 
to mid- April 2020, immediately prior to Tayside's elimination dec-
laration, who acquired HCV via IDU, were eligible.11 Total number 
of HCV- diagnosed PWID includes late- 2016 diagnoses. Individuals 
self- reported injecting status to clinical staff. Follow- up was cen-
sored in mid- December 2020. A de- identified database was created 
and stored on secure servers, with participants allocated unique 
identifiers.
Individual parameters included: CHI; date of birth; gender; and 
post code of most recent residence to derive Scottish Index of 
Multiple Deprivation (SIMD).12 Clinical data included: dates of HCV 
diagnoses; number of treatments; transmission route; genotype; 
treatment pathway; recent IDU; cirrhosis status; BBV co- infection 
status; opioid substitution therapy (OST) status; treatment type; 
treatment start date; treatment completion status; mortality status 
and, if deceased; mortality cause.
2.3 | Testing
HCV RNA testing on plasma samples was undertaken using the 
Hologic Panther platform with HCV Quant Dx Assay13 or the Abbott 
Real- Time m2000sp and m2000rt Polymerase Chain Reaction 
(PCR) platform.14 HCV genotype analysis, including subtyping, used 
an in- house real- time PCR as the front line assay and, if required, 
HCV core Sanger sequencing to determine any genotypes which 
were unclear by real- time PCR, at the Scottish Virology Reference 
Laboratory, NHS Greater Glasgow & Clyde. Dried Blood Spot (DBS) 
RNA samples were tested using an in- house assay15 or the Abbott 
m2000 system.16
2.4 | Patient and public involvement
Patient or public involvement groups were not involved in the design 
of this study. Study design was developed from prior experience of 
the investigators working with the stakeholders involved.
2.5 | Population and outcome definitions
PWID was defined as ever injected drugs (self- reported). Cirrhosis 
was defined as any of the following: Fibroscan reading >18kPa; 
Fib4 >3.46, or confirmation via: liver biopsy; ascites with evidence 
of liver disease; hepatic encephalopathy plus chronic liver disease; 
oesophagogastric varices with patent portal vein. SVR was unde-
tectable HCV RNA at least 12 weeks post- treatment. Relapse was 
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undetectable RNA at end of treatment, but detectable prior to or at 
SVR; or treatment initiation and detectable RNA prior to or at SVR, 
if end of treatment test not conducted. Non- response was detect-
able RNA above the lower limit of detection (10 IU/mL) during treat-
ment. Re- infection was detectable RNA following confirmed SVR, or 
detectable RNA at end of treatment with genotype change. Cause 
of death was classified as: liver related (or not); drug related (in line 
with National Records Scotland; NRS)17 and unknown/other if mor-
tuary record not finalised at censor date, or death occurred outside 
Tayside. Liver- related death was liver disease as primary/secondary 
morality cause on an individual's mortuary record. Although mor-
tality causes could only be obtained for those in Tayside, mortality 
status was determined via CHI number. OST receipt was defined at 
the time of pre- treatment HCV PCR test ±6 months.
2.6 | Treatment pathways
There are six HCV care pathways in Tayside; five in community 
settings. They are named by location: conventional hospital care; 
drug treatment centres; needle exchanges; community pharmacies; 
nurse- led outreach clinics and prisons. All community pathways 
are in environments accessible to PWID. In the nurse- led outreach 
pathway, patients are seen in their local neighbourhood, typically 
in remote areas. Drug treatment clinics are in central locations. 
Testing, pre- treatment assessment, and treatment are available in 
each (ultrasound requires central travel). The needle exchange and 
community pharmacy pathways were initially experimental, imple-
mented through pragmatic pathway trials, which became embedded 
to provide routine testing and treatment.18- 21 All pathways are mul-
tidisciplinary, involving specialist nursing staff, gastroenterologists/
hepatologists, infectious disease physicians, specialist and commu-
nity pharmacists, and psychologists. Nurses and community phar-
macists can prescribe DAAs for simple cases of HCV infection (eg 
treatment naïve and non- cirrhotic), either as independent prescrib-
ers or through Patient Group Direction.22
2.7 | Statistical analysis
Primary outcomes (treatments and SVR) were summarised using 
descriptive statistics, for comparison against targets. Comparison 
of SVR by patient and treatment characteristics were conducted in 
the same manner in intention- to- treat (ITT) and per- protocol (PP) 
populations. The ITT group includes all who initiated treatment, 
and the PP group includes treatment completers. We hypothesised 
that variation in SVR in community pathways compared to special-
ist hospital care would be due to differences in follow- up. Logistic 
regression modelling was used to assess this. Models were adjusted 
for patient characteristics and explored steps in the treatment jour-
ney for the ITT and PP groups, with and without SVR tests. Models 
were adjusted in a stepwise approach for age, gender, cirrhosis, 
and genotype. Where applicable, participants missing SVR were 
assumed treatment failures. P of ≤0.05 was assumed to demonstrate 
statistical significance. Analyses were undertaken using IBM SPSS 
Statistics 25.
2.8 | Re- infection and mortality
Those who achieve SVR are offered annual follow- up RNA test-
ing through all pathways. We measured the efficacy of re- infection 
follow- up by calculating the proportion of cases with follow- up 
RNA tests received in line with local policy (annual re- testing post- 
SVR). We estimated re- infection incidence per 100 person- years 
(PY), assuming a Poisson distribution. Time- at- risk began after 
SVR and ended at last negative RNA test, if not re- infected. If re- 
infected, time- at- risk ended at the mid- point between last nega-
tive RNA test and re- infection date. Where last negative RNA test 
indicated SVR, with no further follow- up tests prior to the censor 
date, cases were excluded. Cases that did not achieve SVR or died 
prior to this were excluded. For cases that were re- infected at time 
of SVR test, that is RNA negative at end- of- treatment, or missing 
end- of- treatment test, then RNA positive at SVR with different 
genotype, the time- at- risk period was from the date of end- of- 
treatment RNA test, or estimated date if test not available, and the 
mid- point between then and date of SVR. Mortality was checked 
up to and including the censor date; rates were based on time- at- 
risk from treatment initiation for primary HCV infection to censor 
date or date of decease.
3  | RESULTS
Annual treatments initiations among PWID in Tayside for the 3 years 
prior to scale- up (2014- 16) were, 126, 138, and 130, giving a cumu-
lative 394 treatments among 387 PWID. During treatment scaleup 
(January 2017 to April 2020), 713 treatments were initiated among 
662 PWID (Figure 1), an 84.5% increase in HCV treatment among 
PWID regionally.
Table 1 outlines descriptive cohort data (tabulated by path-
way in Data S1). All patients were treated with DAAs. All patients 
had an injection history, 77.3% received OST and 51.9% reported 
injecting in the 12 months prior to treatment. Most were male. 
Median age at first treatment was just under 40. Most individ-
uals had a registered postcode in the most deprived areas. HCV 
genotypes 1 and 3 were most common. Co- infection with other 
BBVs was uncommon, and few were diagnosed with cirrhosis. 
Approximately one third were treated through a pragmatic trial 
of a novel pathway.
The majority were treatment naïve prior to the scaleup and, 
among those who were treatment experienced, 9 in 10 treatments 
were based on pegylated interferon (Peg- IFN). Most (88.4%, Table 2) 
completed their course of DAAs. Figure 1 shows outcomes by 
treatment initiation, and cumulative treatment and post- treatment 
outcomes.
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577 SVRs (80.9%) were obtained in the ITT population (n = 713). 
Eighty- two cases did not have an SVR test (lost to follow- up, de-
ceased or moved). Excluding those missing an SVR test in the ITT 
group, SVR was 91.4% (Table 2). In the PP population (n = 630), 536 
SVRs were obtained (85.1%). Excluding 62 PP cases that did not have 
an SVR test, this rose to 95.7%. Loss to follow up (LTFU) varied sub-
stantially across pathways (Table 2).
Of treatment completers, eight died prior to SVR testing. Of 
treatment non- completers (n = 83), 41 (49.4%) obtained SVR, 30 
(36.1%) did not and 12 (14.5%) were missing SVR data. Of those 12, 
8 were LTFU; 3 moved and 1 died. For treatment non- completers 
with documented SVR tests (n = 71), 57.7% obtained a cure.
3.1 | HCV re- infection and follow- up RNA testing
During the study, 236 cases among 231 individuals were followed- up 
for re- infection. Of those who obtained SVR, 39% (227/577) had at 
least one follow- up RNA test. Re- infection occurred 39 times, 9 de-
tected at SVR, over 256.57 PY of follow- up, yielding a rate of 15.20 per 
100 PY (95% CI 10.81- 20.78). Among those who reported recent inject-
ing, there were 142 cases among 140 individuals over 175.43 PY, yield-
ing a rate of 14.82 per 100 PY (95%CI 9.68- 21.72). Among re- infections, 
25 cases were re- treated: 17 obtained SVR, four did not, and four were 
LTFU. Of re- infected individuals, incidence was highest among those in-
itially treated through needle exchanges (Table 3). Of the 25 re- treated 
F I G U R E  1   Post- treatment outcomes of People Who Inject Drugs treated in NHS Tayside 2017- 20. HCV, Hepatitis C Virus; RNA, 
Ribonucleic acid; PWID, People Who Inject Drugs; SVR, Sustained Virologic Response; LTFU, Lost to Follow- up; EoT- and LTFU, End of 
Treatment Negative and Lost to Follow- up. †Five were treated 3 or 4 times. ‡For disclosure reasons, some data are combined. §Of relapses 
and non- responses, eleven completed treatment. It is possible some cases are early re- infections, but the evidence was insufficient to 
classify accordingly
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persons moved§
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10 died prior to test
540 SVR 58 no SVR 64 SVR unknown
51 treatment initiations†
43/51 treatments complete
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577 SVR cases required post-SVR RNA follow-up
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Demographica Gender— n (%)
Male 491 (74.2)
Female 171 (25.8)
Postcode Type— n (%)
Residential 605 (91.4)
Supported living or hostel 41 (6.2)
Prison 16 (2.4)
SIMD postal code quintile— n (%)




(least deprived) 5 8 (1.2)
Not indexed 4 (0.6)
Age in years— median (IQR) [n];
At first HCV diagnosis 34 (28- 40) [662]
At first HCV treatment 39 (34- 46) [662]
At second HCV treatment 40 (36- 47) [46]
Pre- scaleup HCV treatment history— n (%)
Treatment experienced 119 (18.0)
Treatment naïve 543 (82.0)
Pre- scaleup HCV treatments received— n (%)
1 111 (93.3)
2 8 (6.7)
Pre- scaleup HCV treatment type— n (%)
Peg- IFN based 114 (89.8)
DAA based 13 (10.2)
Pre- treatment informationb HCV Genotype— n (%)
1 280 (39.3)
3 403 (56.5)
2 or 4 4 (2.0)
Unknown 16 (2.2)




Report injecting in 12 months




Co- infection with other BBV— n (%)
HIV and or HBV 8 (1.0)
None 705 (99.0)
(Continues)
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cases, 23 (92%) had completed the course of DAAs for their initial infec-
tion. Fourteen cases did not have further treatment within the study 
timeline; four of whom died, with the remaining 10 LTFU.
After obtaining SVR, 87 (15%) of 577 cases had repeat RNA 
testing in the first 12 months, in line with policy. Within two years 
of SVR, 110 (19%) of 577 had follow- up testing. Of those, 20 (18%) 
reflected continued follow- up from the previous year, in line with 
policy. Fifteen were tested within three years, and four within four 
years. The remainder either did not receive follow- up testing or 
had non- standard test intervals (eg <12 months from SVR).
3.2 | Mortality
Fifty- four treated individuals died over a period of 1,553.04 PY, 
yielding an all- cause mortality rate of 3.48 per 100 PY (95% CI 
2.61- 4.54); 29 were drug related, yielding an estimated drug- 
related mortality rate of 1.87 per 100 PY (95% CI 1.25- 2.68). Four 
(9%) deaths were liver- related, due to: hepatocellular carcinoma 
(2); liver metastases and accompanying causes (2). Forty- four 
(81.5%) patients died following SVR, while 10 died before SVR 




Treated via pragmatic trial— n (%)
Yes 263 (36.9)
No 450 (63.1)
Receiving OST prior to treatment— n (%)
Yes 551 (77.3)
No 162 (22.7)
Abbreviations: BBV, blood- borne virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; 
OST, opioid substitution therapy; Peg- IFN, pegylated interferon; people who inject drugs; PWID; SIMD, Scottish Index of Multiple Deprivation.
aDemographic data n = 662.
bPre- treatment data n = 713.
TA B L E  1   (Continued)
TA B L E  2   Intention- to- treat (n = 713) and per- protocol (n = 630) sustained virologic response, treatment initiations, completions, and loss 














Treatments initiated— n (%) 91 (12.8) 46 (6.4) 144 (20.2) 205 (28.8) 124 (17.4) 103 (14.4) 713 (100)
Treatments complete— n (%) 83 (91.2) 41 (89.1) 140 (97.2) 160 (78.0) 112 (90.3) 94 (91.3) 630 (88.4)
SVR— n (%) 74 (81.3) 34 (73.9) 131 (91.0) 155 (75.6) 102 (82.3) 81 (78.6) 577 (80.9)
No SVR— n (%) 17 (18.7) 12 (26.1) 13 (9.0) 50 (24.4) 22 (17.7) 22 (21.4) 140 (19.1)
SVR exc. Unknownb— % 91.4 87.2 95.6 85.6 96.2 93.1 91.4
Loss to follow- upc— n (%) 10 (12.5) 7 (8.8) 7 (8.8) 22 (27.5) 17 (21.2) 17 (21.2) 80 (100)
Per- protocold
SVR— n (%) 70 (84.3) 32 (78.0) 129 (92.1) 133 (83.1) 96 (85.7) 76 (80.9) 536 (85.1)
SVR exc. Unknowne— % 95.9 94.1 96.3 94.3 98.0 95.0 95.7
No SVR— n (%) 13 (15.7) 9 (22.0) 11 (7.9) 27 (16.9) 16 (14.3) 18 (19.1) 94 (14.9)
Loss to follow- upc— n (%) 9 (14.5) 7 (11.3) 4 (6.4) 17 (27.4) 12 (19.4) 13 (21.0) 62 (100)
Abbreviations: exc., excluding; SVR, sustained virologic response.
aNovel care pathway.
bn = 631.
cThose lost to follow- up but believed to reside locally, and those who moved.
dThose who completed treatment.
en = 560.
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3.3 | Treatment pathways
Needle exchanges initiated the highest proportion of treatments 
(Table 2). Collectively needle exchanges and community pharmacies 
initiated almost half of all treatments. Treatment completion was 
highest in pharmacies and lowest in needle exchanges, while LTFU 
was highest in needle exchanges and lowest in pharmacies. SVR 
seemed to vary across pathways in the ITT group. However, among 
treatment completers with a test, SVR rates stabilised in excess of 
90% (Figure 2).
Results for pathway- denominated logistic regressions are pre-
sented in Table 4, with full tabulation in Data S1 (Sections 2 and 3).
Clinical pathway n (%) PY
Incidence per 
100 PYa
Pathway prior to HCV
re- infection (n = 39)
Hospital 0 (0.0) 22.93 0.00 
(0.00- 16.09)b
Community pharmacies 12 (30.8) 92.25 13.01 
(6.72- 22.73)
Needle exchanges 19 (48.7) 64.08 29.65 
(17.85- 46.30)
Otherc 8 (20.5) 77.31 10.35 
(4.47- 20.39)
Abbreviations: HCV, hepatitis c virus infection; PWID, people who inject drugs; PY, person- years of 
observation.
a95% confidence interval indicated in brackets.
bOne- sided p, 97.5% confidence interval.
cFor disclosure reasons, drug treatment centres; nurse- led community clinics; and prison pathways 
are combined.
TA B L E  3   Clinical pathways for HCV 
re- infected PWID in Tayside 2017- 20
F I G U R E  2   Proportion of sustained virologic response among people who inject drugs by treatment pathway. †All treatment initiations, 
those without SVR test assumed treatment failures (n = 713). ‡All treatment initiations with a related SVR test (n = 631). §All treatments 
were completed, those without SVR test assumed treatment failures (n = 630). ¶All treatments were confirmed completed, with a 
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C A R E
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P H A R M A C I E S
N E E D L E  
E X C H A N G E S
N U R S E-L E D  
C O M M U N I T Y  
C L I N I C S
P R I S O N S
SVR ITT group† SVR ITTgroup 
with SVR test‡
SVR PP Group§ SVR PP Group
with SVR test¶
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The unadjusted model in the ITT population (n = 713) implied 
that those treated through community pharmacies had higher 
odds of achieving SVR (OR 2.32 [1.07- 5.03], P ≤ 0.05). However, 
adjusted for patient characteristics, this became marginally non- 
significant (OR 2.17 [.95- 4.94], P = 0.066). There were no signifi-
cant differences between pathways in the ITT group who attended 
for SVR. In the PP groups with (n = 630) and without (n = 560) SVR 
test, there were also no significant differences in SVR between 
pathways.
In the PP group, adjusted for age and gender, the model implied 
that female gender may be associated with reduced odds of SVR (OR 
0.59 [.35- 1.01], P = 0.056). Of females who did not obtain SVR in this 
model, for 66.7% (18/27) this was due to LTFU after treatment com-
pletion. Suggesting that, following treatment completion, follow- up 
TA B L E  4   Logistic regression modelling of sustained virologic response by treatment pathway
Model N Variable SVR— n (%)
Unadjusted Adjusted
OR (95% CI) P aOR (95% CI) P





34 (73.9) 0.65 (0.28- 1.51) 0.318 0.60 (0.25- 1.42) 0.243
Community 
pharmacies
131 (91.0) 2.32 (1.07- 5.03) <0.05 2.16 (0.95- 4.90) 0.066
Needle exchanges 155 (75.6) 0.71 (0.39- 1.32) 0.280 0.63 (0.32- 1.23) 0.172
Nurse- led community 
clinics
102 (82.3) 1.07 (0.53- 2.15) 0.860 0.97 (0.46- 2.02) 0.930
Prison 81 (78.6) 0.85 (0.42- 1.72) 0.643 0.63 (0.29- 1.38) 0.247
ITT
with SVR test





34 (87.2) 0.64 (0.19- 2.17) 0.477 0.61 (0.17- 5.16) 0.440
Community 
pharmacies
131 (95.6) 2.07 (0.67- 6.38) 0.207 1.85 (0.56- 6.18) 0.315
Needle exchanges 155 (85.6) 0.56 (0.23- 1.36) 0.202 0.50 (0.19- 1.33) 0.496
Nurse- led community 
clinics
102 (96.2) 2.41 (0.68- 8.54) 0.172 2.14 (0.58- 7.97) 0.256
Prison 81 (93.1) 1.28 (0.41- 3.97) 0.673 1.10 (0.31- 3.88) 0.881





32 (78.0) 0.66 (0.26- 1.70) 0.390 0.57 (0.21- 1.55) 0.274
Community 
pharmacies
129 (92.1) 2.18 (0.93- 5.12) 0.074 1.93 (0.77- 4.87) 0.163
Needle exchanges 133 (83.1) 0.92 (0.44- 1.88) 0.280 0.75 (0.34- 1.67) 0.480
Nurse- led community 
clinics
96 (85.7) 1.11 (0.50- 2.47) 0.789 0.96 (0.41- 2.24) 0.928
Prison 76 (80.9) 0.78 (0.36- 1.72) 0.543 0.52 (0.22- 1.27) 0.152
PP
with SVR test





32 (94.1) 0.69 (0.11- 4.31) 0.687 0.46 (0.07- 3.17) 0.429
Community 
pharmacies
129 (96.3) 1.11 (0.26- 4.77) 0.893 0.62 (0.12- 3.18) 0.569
Needle exchanges 133 (94.3) 0.71 (0.18- 2.77) 0.621 0.40 (0.09- 1.87) 0.246
Nurse- led community 
clinics
96 (98.0) 2.06 (0.34- 12.64) 0.436 1.34 (0.20- 8.88) 0.760
Prison 76 (95.0) 0.71 (0.18- 3.78) 0.793 0.96 (0.71- 1.01) 0.107
Abbreviations: aOR, adjusted odds ratio; ITT, intention- to- treat; OR, odds ratio; PP, per protocol; SVR, sustained virologic response.
The conventional hospital pathway is the reference group for all models.
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for females may require attention across all pathways, as the effect 
fell away in the PP group with an SVR test (Data S1, Tables 2.8 and 
2.9). Models combining all community pathways into one compara-
tor were non- significant across all groups (Data S1, Section 3).
Figure 2 shows the estimated HCV cascade of care in Tayside, 
measured against local and WHO targets. It suggests that Tayside 
diagnosed the majority of the estimated infected PWID population 
and met the targets set for regional scaleup. Further, WHO diagnosis 
and treatment targets appear to have been met in line with baseline 
infection estimates (Figure 3).
4  | DISCUSSION
Rapid regional HCV treatment scale- up in PWID was achieved in 
Tayside. There were over 700 treatments across six pathways in 
three years, a close to two- fold increase on previously high levels of 
HCV treatment among PWID in Tayside. The estimated care cascade 
shows that 90% of the estimated HCV- infected PWID population 
were diagnosed and 92% of those initiated treatment. SVR in the ITT 
group was over 80% and exceeded 90% in those with a documented 
test. Among treatment completers, SVR exceeded 85% and was over 
95% for those with a documented test. Pharmacies and needle ex-
changes made substantial contributions, delivering almost half of all 
treatments. Our data adds strong population- level evidence to the 
literature supporting HCV care in community pharmacies.21,23,24,25
Our findings suggest a high level of attrition at the post- treatment 
follow- up point among our cohort of PWID. This contrasts with data 
from, for example, the Icelandic national scaleup among PWID, 
which reported minimal attrition at each step of the HCV cascade of 
care.26 The statistical analyses initially implied that receiving treat-
ment through a community pharmacy was associated with higher 
odds of SVR. However, in the ITT population who attended for SVR, 
there were no significant differences between community pathways 
and hospital care. This implies differences in SVR were caused by 
variation in follow- up and that, irrespective of treatment completion, 
pharmacies provided superior follow- up for SVR testing. The mod-
els further suggested that SVR did not vary by treatment pathway 
or patient characteristics among those who completed treatment. 
One part- adjusted model was significant which implied that when 
accounting for treatment pathway, age and gender, female gender 
was weakly associated with reduced odds of SVR. Consequently, 
targeted follow- up initiatives may be required to improve follow- up 
for SVR testing among females across all pathways.
F I G U R E  3   Estimated HCV Care Cascade in Tayside population of People Who Inject Drugs, alongside targets and outcomes for HCV 
diagnosis and treatment in the scaleup period. Est, estimated; HCV, hepatitis c virus; PWID, people who inject drugs; SVR, sustained 
virologic response; WHO, World Health Organization. Note: percentages rounded to the nearest whole number. Intention- to- treat and per- 
protocol rates were reported for SVR. †Based on 29% estimated chronic infection in a population of 2,800 people who inject drugs. ‡Total 
with ≥one HCV RNA positive test from June 2016 to April 2020 on the national clinical database. 2016 diagnoses included as they will have 
been eligible for treatment at beginning of treatment scaleup in 2017. §Proportion of all treated cases (not treated individuals). SVR was 91% 
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The data indicate high deprivation, in line with national esti-
mates, and reinforces evidence that HCV disproportionately im-
pacts the most disadvantaged.27- 29 This Tayside cohort is relatively 
young, with low incidence of BBV co- morbidity. However, mor-
tality risk in the population was notable, and over half of deaths 
were drug related. This aligns with reports suggesting Tayside has 
the second- highest rate of DRDs in Scotland and implies that ser-
vice improvements are required to reduce drug- related harms.30,31 
Compared to a recent cohort study of drug- related mortality 
among HCV- infected PWID from 2009- 18— in which Tayside res-
ident PWID had an equivalent drug- related morality rate of 1.02 
per 100 PY, the highest of the four4 largest Scottish health boards, 
and all Scottish PWID had an equivalent rate of 1.24 per 100 
PY— our observed mortality rate is concerningly high.32 Ongoing 
re- infection and mortality risks in our cohort suggest substance 
misuse and harm reduction services for PWID in Tayside must 
improve.
The high proportion of cure adds valuable real- world evidence 
to existing literature demonstrating the efficacy of DAAs for treat-
ing HCV in PWID.5,6 The highest proportion of SVR (excluding un-
knowns) in ITT analysis was in the nurse- led community pathway. 
In this pathway, diagnosis and DAA prescribing are undertaken by 
nurses. Similarly, in the pharmacy pathway, diagnosis and treatment 
can be wholly facilitated by the pharmacist through the use of sim-
plified DAA prescribing algorithms and the use of dried blood spot 
sampling. The outcomes in our cohort strengthen the case for task- 
shifting elements of care which can be completed in the community 
into the community for PWID.33- 35
Our data augments the literature suggesting re- treatment fol-
lowing re- infection should be offered without stigma or discrimina-
tion.36,37 Despite the high re- infection rate among the subset with 
follow- up— which aligns with national re- infection estimates— recent 
data demonstrated a reduction in chronic HCV among PWID in 
Tayside, consistent with the rapid sale- up.38,39 The high re- infection 
rate among needle exchange clients in this cohort is consistent with 
prior longitudinal studies from Tayside— which predominantly stud-
ied those treated with Peg- IFN based therapies since 1998— but the 
overall rate observed in our study is considerably higher, and may 
imply a temporal change in the risk of re- infection concurrent to the 
shift to DAA- only treatment.40 This rate, particularly compared to a 
recent meta- analysis which found lower re- infection rates (6.2/100 
PY; 95% CI 4.3- 9.0) among recent injectors, is not surprising in this 
early phase.41 It implies we treated those most likely to drive HCV 
transmission locally, and we hypothesise it will decrease as the 
population level benefits of the scaleup are realised and additional 
follow- up is completed. Continued follow- up and re- treatment of 
re- infection in coming years is the basis of the TasP study to drive 
chronic HCV to below 10%.
Data reported here affirms existing evidence that completing 
treatment with DAAs elicits high SVR rates among PWID.5 This sug-
gests that if HCV treatment is adequately supported, SVR will likely 
be achieved. Recent treatment guidelines noted the potential to 
omit SVR testing.36 Our data suggest that, for those who complete 
treatment, it may be feasible to omit SVR testing whilst assuming 
treatment was successful. This may stimulate further discussion on 
whether the primary goal of HCV treatment is obtaining SVR or con-
firmed treatment completion. However, we acknowledge that omit-
ting SVR testing may only be desirable in simpler cases of infection 
or in contexts where re- infection is low.42
4.1 | Limitations
This study is limited by its observational nature, its reliance on rou-
tinely collected data, and the lack of a comparator cohort, which is 
the basis of the next phase of the study. During data collection, some 
assumptions were made, for example if date of infection was unavail-
able a surrogate was used, such as treatment initiation date, which 
may have affected person- time estimates. Further, most cases that 
resulted in SVR were missing post- SVR RNA testing, which limited 
re- infection estimates. Finally, the NHS is free for patients: possibly 
limiting international transferability of the care model. However, this 
study's strength lies in its rich description of the PWID population 
and the unique investigation of TasP in the context of HCV elimina-
tion on a regional level using real- world data.
5  | CONCLUSIONS
Our analyses indicate that Tayside achieved pre- specified local di-
agnosis, treatment, and SVR targets set for the TasP scale- up pro-
gramme. Further, Tayside has met WHO testing and treatment 
targets having diagnosed 90% of the estimated PWID population 
with HCV, and treated over 80% of cases.1 Our data implies that 
rapid regional scale- up of HCV treatment for PWID can be achieved 
through novel multi- stakeholder pathways focussed on shifting test-
ing, DAA prescribing, and treatment into community settings. To our 
knowledge, is the first real- world study from the United Kingdom to 
demonstrate the effects of rapid regional HCV treatment scaleup 
among PWID, highlight the benefits of utilising non- specialist pre-
scribers regionally, and quantitatively compare novel community 
pathway contributions to scaling up HCV treatment.
The re- infection rate, and proportion of DRDs, suggests we 
reached the highest- risk individuals for transmission of HCV and 
implies that harm reduction and substance misuse services in the 
region need strengthening. Other areas targeting PWID to achieve 
elimination should provide substantial- related care in these respects 
alongside comprehensive testing and easy access to treatment.
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